Kim Kramer, MD

In my research, I am investigating novel treatments to eliminate microscopic tumor cells in the central nervous system. These novel treatments include monoclonal antibodies attached to radioactive substances (radioimmunotherapy) that we give directly into the cerebrospinal fluid. We are one of the few programs in the world committed to the cure of cancers of the leptomeninges (the two innermost tissue layers that cover the brain and spinal cord). The use of targeted radioimmunotherapy is promising because it could reduce our reliance on external-beam radiation therapy to the brain, which can cause developmental delays in some young children. We are exploring new ways to target tumor cells while sparing the central nervous system and the rest of the body from the side effects of radiation.

In addition to caring for patients and conducting research, I am active in teaching residents who are rotating through our service. I have had the special opportunity to mentor several fellows and medical students. I am honored to be part of the MSK Kids team — including researchers, nurses, nurse practitioners, social workers, and research assistants — who are committed to improving outcomes for our patients.

I am also motivated by the inspirational parents of our patients, who are dedicated to driving legislation that supports funding for and awareness of these cancers. They, too, are vital members of our team. I am proud to be an active Board member on Kids V Cancer, Cookies for Kids Cancer, and Arms Wide Open, all initiated and run by our incredible parent community. Our ultimate goal is to see our patients come back to see us years from now, doing well and thriving.